On July 13, the pharmaceutical company held a semi-annual business analysis meeting in Jinxi Pharmaceutical Factory to summarize the completion of the pharmaceutical company's work in the first half of the year, analyze the existing problems, and deploy the work in the second half of the year.

Members of the management team of pharmaceutical companies and subordinate enterprises, as well as the chief and deputy managers of functional departments, attended the meeting. The meeting listened to the summary of the work of 9 subordinate enterprises and 5 functional departments in the first half of the year and the report on the work arrangement in the second half of the year. Gong Xiliang, chief financial officer of the pharmaceutical company, made a financial analysis of the operating situation in the first half of the year.

Huang Jinlong, general manager of the pharmaceutical company, pointed out the highlights and problems of the work in the first half of the year, and arranged the work objectives, plans and ideas for the second half of the year. He said that in the first half of the year, pharmaceutical companies have made certain achievements in industrial sales, pharmaceutical commerce, scientific and technological research and development, improving work efficiency, enriching variety structure, and financial management. He hopes that in the second half of the year, under the premise of ensuring quality, safety, and environmental protection, pharmaceutical companies will continue to grasp the progress of project technological transformation and tap new profit growth points; grasp joint reorganization and rapidly expand the scale of the enterprise; grasp marketing innovation, Improve marketing capabilities; accelerate product development, improve development quality; practice internal skills, standardize management, and improve management; accelerate the internationalization of preparations, and continuously improve the company's quality management level.